TY - JOUR
T1 - Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children
T2 - a systematic review and meta-analysis
AU - Nair, Harish
AU - Nokes, D. James
AU - Gessner, Bradford D.
AU - Dherani, Mukesh
AU - Madhi, Shabir A.
AU - Singleton, Rosalyn J.
AU - O'Brien, Katherine L.
AU - Roca, Anna
AU - Wright, Peter F.
AU - Bruce, Nigel
AU - Chandran, Aruna
AU - Theodoratou, Evropi
AU - Sutanto, Agustinus
AU - Sedyaningsih, Endang R.
AU - Ngama, Mwanajuma
AU - Munywoki, Patrick K.
AU - Kartasasmita, Cissy
AU - Simões, Eric AF
AU - Rudan, Igor
AU - Weber, Martin W.
AU - Campbell, Harry
N1 - Funding Information:
BDG has received honoraria from GlaxoSmithKline, but has not received any funding for work on respiratory syncytial virus. RJS has received grant funding from MedImmune and Wyeth. KLO'B has received grant funding from MedImmune. PFW has received grant funding and honoraria from Sanofi-Aventis, Wyeth, MedImmune, and Merck; however no grants or honoraria were received for the work included in this study. AC has received grant support from Wyeth and MedImmune. CK has received grant funding from Wyeth and Abbott; however no funding was received for work included in this study. EAFS has received research grants and honoraria from Medimmune, research grants from Abbott International, and honoraria from GlaxoSmithKline and Sanofi Pasteur; however no grants or honoraria were received for work included in this study. HN, DJN, MD, SAM, AR, NB, ET, AS, ERS, MN, PKM, IR, MWW, and HC declare that they have no conflicts of interest.
Funding Information:
This work was done as part of the wider programme of the Child Epidemiology Reference Group (CHERG) to establish the major causes of global childhood disease burden. We thank Emelda A Okiro, Ann Bett, John Abwao (KEMRI-Wellcome Trust Research Programme, Kenya); Dana Bruden (Arctic Investigations Program, National Center for Preparedness, Detection and Control of Infectious Disease, CDC, Anchorage, AK, USA); Byron Arana (Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala); Keith P Klugman (University of the Witwatersrand/Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Hubert Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, GA, USA); Pedro Alonso (Barcelona Centre for International Health Research (CRESIB), Hospital Clínic/IDIBAPS, Universitat de Barcelona, Spain and Centro de Investigação em Saúde da Manhiça (CISM), Ministerio de Saúde, Mozambique); Llorenç Quintó (Barcelona Centre for International Health Research (CRESIB), Hospital Clínic/IDIBAPS, Universitat de Barcelona, Spain); Kuswandewi Mutyara (Medical Faculty, Padjadjaran University, Hasan Sadikin General Hospital, Bandung, Indonesia); Lesley C McGoohan (Centre for Population Studies, Global Health Academy, The University of Edinburgh) assistance with some of the illustrations in this report; and Douglas Holtzman (Bill & Melinda Gates Foundation, Seattle, WA, USA) for participating in the expert group meeting in Edinburgh and reviewing the report. Financial support for this work was provided by WHO CAH (grant number WHO OD/AP-07-04680 ) and the Bill & Melinda Gates Foundation ( R41202 ). Studies from Kilifi, Kenya received Wellcome Trust funding ( 061584 , 076278 ). AR was supported by a grant from the Spanish Ministry of Education and Science (Ramón y Cajal: RYC-2008-02777 ). MWW is a WHO staff member; he is responsible for the views expressed in this publication and they do not necessarily represent the decisions or the policies of WHO.
PY - 2010
Y1 - 2010
N2 - Background: The global burden of disease attributable to respiratory syncytial virus (RSV) remains unknown. We aimed to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to RSV in children younger than 5 years in 2005. Methods: We estimated the incidence of RSV-associated ALRI in children younger than 5 years, stratified by age, using data from a systematic review of studies published between January, 1995, and June, 2009, and ten unpublished population-based studies. We estimated possible boundaries for RSV-associated ALRI mortality by combining case fatality ratios with incidence estimates from hospital-based reports from published and unpublished studies and identifying studies with population-based data for RSV seasonality and monthly ALRI mortality. Findings: In 2005, an estimated 33·8 (95% CI 19·3-46·2) million new episodes of RSV-associated ALRI occurred worldwide in children younger than 5 years (22% of ALRI episodes), with at least 3·4 (2·8-4·3) million episodes representing severe RSV-associated ALRI necessitating hospital admission. We estimated that 66 000-199 000 children younger than 5 years died from RSV-associated ALRI in 2005, with 99% of these deaths occurring in developing countries. Incidence and mortality can vary substantially from year to year in any one setting. Interpretation: Globally, RSV is the most common cause of childhood ALRI and a major cause of admission to hospital as a result of severe ALRI. Mortality data suggest that RSV is an important cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b. The development of novel prevention and treatment strategies should be accelerated as a priority. Funding: WHO; Bill & Melinda Gates Foundation.
AB - Background: The global burden of disease attributable to respiratory syncytial virus (RSV) remains unknown. We aimed to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to RSV in children younger than 5 years in 2005. Methods: We estimated the incidence of RSV-associated ALRI in children younger than 5 years, stratified by age, using data from a systematic review of studies published between January, 1995, and June, 2009, and ten unpublished population-based studies. We estimated possible boundaries for RSV-associated ALRI mortality by combining case fatality ratios with incidence estimates from hospital-based reports from published and unpublished studies and identifying studies with population-based data for RSV seasonality and monthly ALRI mortality. Findings: In 2005, an estimated 33·8 (95% CI 19·3-46·2) million new episodes of RSV-associated ALRI occurred worldwide in children younger than 5 years (22% of ALRI episodes), with at least 3·4 (2·8-4·3) million episodes representing severe RSV-associated ALRI necessitating hospital admission. We estimated that 66 000-199 000 children younger than 5 years died from RSV-associated ALRI in 2005, with 99% of these deaths occurring in developing countries. Incidence and mortality can vary substantially from year to year in any one setting. Interpretation: Globally, RSV is the most common cause of childhood ALRI and a major cause of admission to hospital as a result of severe ALRI. Mortality data suggest that RSV is an important cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b. The development of novel prevention and treatment strategies should be accelerated as a priority. Funding: WHO; Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=77951653074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951653074&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(10)60206-1
DO - 10.1016/S0140-6736(10)60206-1
M3 - Article
C2 - 20399493
AN - SCOPUS:77951653074
SN - 0140-6736
VL - 375
SP - 1545
EP - 1555
JO - The Lancet
JF - The Lancet
IS - 9725
ER -